Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219
Titel:
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219
Auteur:
Melosky, Barbara Bradbury, Penelope Tu, Dongsheng Florescu, Marie Reiman, Anthony Nicholas, Garth Basappa, Naveen Rothenstein, Jeffrey Goffin, John R. Laurie, Scott A. Wheatley-Price, Paul Leighl, Natasha Goss, Glenwood Reaume, M. Neil Butts, Charles Murray, Nevin Card, Cynthia Ko, Jenny Blais, Normand Gray, Samantha Lui, Hongbo Brown-Walker, Pamela Kaurah, Pardeep Prentice, Leah M. Seymour, Lesley